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Inhibition of acethylcholinesterase (AChE) as a key molecular event induced by 
organophosphate (OP) pesticides and nerve agents presents a human health concern. In 
efficacy testing of experimental oximes, potential antidotes in OP poisoning, reactivation of 
OP-inhibited AChE is used as specific endpoint. However, according to our best knowledge, 
so far oximes have not been quantitatively evaluated by comprehensive benchmark dose 
(BMD) approach, that would improve both identification and quantification of the effect and 
allow more rigorous comparison of efficacies. Thus, we have examined in vivo dose-response 
relationship for two promising experimental oximes, K203 and K027, concerning reactivation 
of erythrocyte AChE inhibited by dichlorvos (DDVP). Groups of Wistar rats were treated 
with six different doses of oximes (i.m) immediately after DDVP challenge (s.c) and AChE 
was measured 60 min later. Dose-response modeling was done by PROAST software 65.5 
(RIVM, The Nederlands). BMD-covariate method resulted in four-parameter model from 
both exponential and Hill model families as the best estimate of relationship between AChE 
activity and oxime dose, with potency parameter being oxime-dependent. Oxime K027 was 
shown to be 1.929-fold more potent considering that 58% increase in AChE activity was 
achived with the dose BMD58-K027 = 52 µmol/kg in contrast to BMD58-K203 = 100 
µmol/kg.  
 
Keywords: dichlorvos, K027 vs K203, rat erythrocytes, benchmark dose, PROAST  
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1. Introduction     1 
Oxime reactivators are chemical compounds used as causal antidotes for the treatment of 2 
human poisoning with organophosphorus compounds (OP). Human exposure to OPs may 3 
arise from the use of OP nerve agents in terrorist attacks, from an occupational exposure to 4 
OP pesticides or from the suicidal self-poisonings. The principal mechanism of action of 5 
oximes is reactivation of OP-inhibited enzyme acetylcholinesterase (AChE, EC 3.1.1.7) and 6 
consequently recovery of the enzyme’s physiological function (Hobbiger, 1963). Successful 7 
reactivation can terminate overstimulation of muscarinic and nicotinic receptors by 8 
acetylcholine (ACh) and thus prevent neurotoxicity (Mileson et al., 1998; Pope et al., 2005). 9 
However, experimental results and clinical findings have demonstrated insufficient and/or 10 
unequal therapeutic value of structurally-different oximes against structurally-different OPs 11 
(Antonijevic and Stojiljkovic, 2007; Eyer, 2003; Worek et al., 2016). Thus, the therapy of 12 
human OP poisoning still presents a demanding issue and the search for oxime with higher 13 
efficacy and/or a broader spectrum of activity compared to clinically used oximes is a 14 
challenging task. Moreover, heterogeneity of used experimental and epidemiological 15 
methodologies makes a rigorous evaluation and comparison of efficacies of both clinically 16 
used and promising experimental oximes difficult (Worek and Thiermann, 2013).  17 
Nevertheless, traditionally in the in vivo testing, effects of oximes have been evaluated at only 18 
one or two different doses in the same experimental protocol and the common way of 19 
analysing dose-response data has been statistical testing of each dose group against the 20 
controls. That approach enables qualitative evaluation of oximes efficacies in order to 21 
differentiate compounds that are able to elicit a significant positive response. However, 22 
quantitative evaluation of oximes would improve both identification and quantification of the 23 
effect and allow more rigorous comparison of their efficacies. Quantitative evaluation of 24 
dose-response relationship as a whole has been enabled by Benchmark Dose (BMD) 25 
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methodology introduced by (Crump 1984).. The BMD approach involves statistical analysis 26 
of the relationship between dose and response to define the dose (BMD) required to elicit a 27 
pre-specified change in response (benchmark response, BMR). The BMD is estimated from 28 
the complete dose-response dataset by fitting dose-response models. Analysing historical 29 
(“available”) data, (Slob and Setzer, 2014) have shown that large number of toxicological 30 
endpoints (both in vitro and in vivo), including AChE activity, can be adequately described by 31 
4-parameter exponential or Hill model family. Statistical uncertainty in estimated BMD value 32 
is presented as the confidence interval around the BMD (lower, BMDL and upper, BMDU 33 
limit). At present, BMD approach is increasingly used for the evaluation of toxicity dose-34 
response data and calculation of BMD as a point of departure for deriving human exposure 35 
limits in human health risk assessment (EFSA, 2017, 2009; Slob, 2002). Moreover, BMD 36 
approach implies a considerable step forward from the perspective of the principles of the 3Rs 37 
(Replacement, Reduction and Refinement) in animal experimentation, in particular in R of 38 
reduction, because all animals in experiment contribute to BMD calculation, alowing getting 39 
more information from the same number of animals (Slob, 2014a, 2014b). 40 
Thus, the specific aim of this sudy was to quantitatively evaluate and compare efficacies of 41 
two promising experimental oximes, K203 and K027, considering reactivation of OP-42 
inhibited AChE using comperhensive BMD approach.  43 
We performed in vivo study on experimental rats acutely exposed to OP insecticide dichlorvos 44 
(DDVP), used as dimethyl OP-structural model compound with oxon moiety that provides 45 
direct inhibition of AChE. Towards DDVP-inhibited erythrocyte AChE we confronted oximes 46 
K203 and K027, with characterized in vitro reactivating and in vivo therapeutic and 47 
reactivating potencies against different OPs  (Antonijevic et al., 2018, 2016; Arshad et al., 48 
2018; Berend et al., 2012; Jun et al., 2010; Kassa et al., 2008; Kovarik et al., 2009; Kuca et 49 
al., 2018, 2010; Lorke et al., 2008; Musilek et al., 2010, 2008, 2007a, 2007b; Musilova et al., 50 
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2009; Petroianu et al., 2007a, 2007b, 2006b, 2006a). In contrast to published in vivo 51 
experimental protocols, that tested one or rarely two oxime doses, here we have tested six 52 
different doses of oximes K203 and K027, with primary aim to model their dose-response 53 
relationships, secondary to quantify size of the AChE-reactivating effect with corresponding 54 
effective doses and the third to quantitatively compare them.  55 
We have applied recently developed advanced BMD methodology – combined BMD 56 
covariate method – that permits simultaneous analyses of multiple dose-response datasets for 57 
a shared endpoint (Slob, 2002; Slob and Setzer, 2014), because it has been shown that it 58 
improves the precision of each individual BMD estimate (Slob and Setzer, 2014; Wills et al., 59 
2016a, 2016b).  60 
Moreover, we have applied estimate of BMD confidence intervals, being recently shown as 61 
robust way for compound potency ranking within and/or across endpoints (Long et al., 2018; 62 
Wills et al., 2017, 2016a, 2016b).  63 
We have also assessed and discussed the importance of appropriately defining benchmark 64 
response values (BMRs) in evaluation of oximes as reactivators of OP-inhibited AChE. 65 
 66 
2. Materials and methods 67 
2.1. Animals 68 
All experimental procedures were approved by the Ethical Committee on Animal 69 
Experimentation of the University of Belgrade, Faculty of Pharmacy (Serbia, No. 323-07-70 
00363/2017-05) and were carried out in accordance with the Animal Welfare Act of the 71 
Republic of Serbia (Official Gazette of the Republic of Serbia No. 41/2009) and Directive 72 
2010/63/EU on the Protection of Animals Used for Scientific Purposes. Male outbred Wistar 73 
rats were purchased from the Military Medical Academy (Belgrade, Serbia). They were 74 
housed in polycarbonate cages (425×266×185 mm3, up to five rats per cage, randomly 75 
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selected) in access- and climate-controlled rooms for seven days of acclimatization before the 76 
experimental procedure. The room temperature was 22 ± 2 °C, the relative humidity 55 ± 77 
10%, the illumination 120 lx and the 12/12 h light/dark cycle (light on at 6:00 h). Food and 78 
tap water were available ad libitum. The food was standard maintenance chow for rats 79 
purchased from The Veterinary Institute Subotica (Subotica, Serbia). Experimental procedure 80 
was carried out on eight weeks old rats weighing 180-200 g. 81 
2.2. Chemicals 82 
Dichlorvos (DDVP, O,O-dimethyl-O-2,2-dichlorovinyl phosphate, CAS number: 62-73-7) 83 
was obtained as a gift from Chemical Agrosava d.o.o. (Belgrade, Serbia) and was 98.8% pure. 84 
Oxime K203 (4-carbamoyl-1-[(2E)-4-{4-hydroxyiminomethylpyridinium-1-yl}but-2-en-1-85 
yl]pyridinium dibromide) and K027 (4-carbamoyl-1-(3-{4-hydroxyiminomethylpyridinium-1-86 
yl}propyl)pyridinium dibromide) were synthesized at the Department of Chemistry, Faculty 87 
of Science, University of Hradec Kralove (Czech Republic) and they were more than 98% 88 
pure. Their purity was analysed using a HPLC technique. Chemical structures, names, and 89 
molecular weights  of OP insecticide DDVP and tested oximes are presented in Table 1. 90 
A stock solution of DDVP was prepared in isopropyl alcohol and further dilutions were made 91 
in distilled water ex tempore. Oximes were dissolved in distilled water and diluted to the 92 
required concentration ex tempore. All other chemicals and reagents of analytical grade were 93 
obtained commercially. 94 
 95 
Table 1 96 
 97 
2.3. Study design and experimental procedure 98 
Study design for the purpose of dose-response analysis for oximes considering reactivation of 99 
DDVP-inhibited AChE was based on following: 1) optimal study design for the estimation 100 
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BMD in continuous endpoints with large coefficient of variation (CV≥18%) was found to be 101 
six dose groups (Slob et al., 2005); 2) analysis of 32 in vivo studies derived standard deviation 102 
of 18.6% in OP-inhibited AChE as an endpoint (Slob, 2017; Slob and Setzer, 2014). Thus, we 103 
have set six dose groups (including zero dose) for each oxime. Rats were divided into 11 104 
experimental groups (5 per group) as follows: group 1 = DDVP; groups 2-6 = DDVP+K203 105 
and groups 7-11 = DDVP+K027. Rats were injected subcutaneously (s.c) over the flank with 106 
DDVP at a dose 30 µmol/kg, which had been reported to cause less than 50% lethality in 107 
unprotected animals (Antonijevic et al., 2016). Immediately after DDVP injection the rats 108 
were injected with oxime dose (Table 1) intramuscularly (i.m), into the back of the thigh. The 109 
highest dose of tested oxims had been reported to cause less than 110 
50% lethality (Antonijevic et al., 2016). Both administrations were done via a 27G 111 
needle/syringe system. All compounds were administrated at a volume of 1 mL/kg body 112 
weight (b.w.). Treatments were performed in the mornings between 8 and 9 a.m. The rats 113 
were humanely euthanized 60 min after the treatment, expecting at that time maximal severity 114 
of intoxication (Antonijevic et al., 2016; Duarte et al., 2012). 115 
 116 
 117 
 118 
2.4. Processing of the tissue and biochemical assay 119 
Blood samples were collected into heparinized syringes by intracardial punction and were 120 
analysed immediately after specimen collection. Erythrocytes were separated by 121 
centrifugation at 3000 xg for 15 min, washed three times in saline solution (0.9% NaCl) and 122 
hemolysed in distilled water (1:600, v/v). Activity of AChE was determined by the modified 123 
spectrophotometric method of (Ellman et al., 1961) using acetylthiocholine iodide (Acros 124 
Organics, USA) as substrate in a final concentration of 1.75 mM (stock solution 35 mM), 125 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
phosphate buffer (pH=7.4) and temperature 25 °C. Absorbance was read at 412 nm using 126 
Cary60 UV-Vis spectrophotometer with a Cary single cell Peltier for temperature control 127 
(Agilent Technologies, USA). AChE activity was expressed in unites µmol of hydrolyzed 128 
acetylthiocholine iodide/min per mL erythrocytes. 129 
2.5. Dose-response data analysis 130 
BMD analysis, statistical analysis of the dose-response data, was conducted using PROAST 131 
software version 65.5 in the R computing environment (Dutch National Institute for Public 132 
Health and the Environment (RIVM)). PROAST v65.5 is available for free download at 133 
http://www.proast.nl. As recommended by the European Food Safety Authority (EFSA) for 134 
continuous type of data, the analysis was done using both the exponential and the Hill model 135 
families (EFSA, 2017, 2009). PROAST uses Akaike information criterion (AIC) to arrive to 136 
the optimal model within model family, where the model with the lowest AIC is selected 137 
(EFSA, 2017). Briefly, a dose-related trend is conifrmed if AIC is lower than the AIC of the 138 
specific null model – 2 units (AIC<AICnull–2). The null model expresses the situation that 139 
there is no dose-related trend, i.e. it is a horizontal line (y=a), and it tends to show the largest 140 
AIC. Further, the lowest AIC should not exceed the AIC of the specific full model by more 141 
than 2 units (AIC<AICfull+2). The full model describes the dose–response relationship simply 142 
by the observed (mean) responses at the tested doses, without assuming any specific dose–143 
response and it tends to show the smallest AIC. 144 
In both model families, y denotes the response, x the dose, while var, a, b, c and d are 145 
parameters to be estimated by fitting the model with same interpretation in both model 146 
families. Parameter var reflects within-group variation, a reflects the background response 147 
(response at x=0, vertical scaling parameter), parameter b relates to the potency of the 148 
chemical (horizontal scaling parameter, in the exponential model, b1/d is directly proportional 149 
to potency, while in the Hill, 1/b is directly proportional to potency), parameter c reflects 150 
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maximum response (maximum fold-change relative to the background response, shape 151 
parameter) and parameter d reflects the steepness of the curve (shape parameter) (Slob and 152 
Setzer, 2014). The combined BMD covariate approach was used, where "oxime" was set as 153 
covariate, factor discriminating the dose-response subgroupings. The combined BMD 154 
covariate approach, identifies the model parameters that are significantly different for each 155 
subgroup, alongside those that can be considered constants across subgroups (Slob, 2002). 156 
Parameters that were not significantly different were kept the same for both tested oximes in 157 
analysis. This combined approach was recently shown to improve the precision of each 158 
individual BMD estimate as all dose-response datasets included in analysis contribute to 159 
individual BMD estimate (Slob and Setzer, 2014; Wills et al., 2016a, 2016b).  160 
Benchmark dose (BMD) is derived from a fitted model as a result of pre-specified change 161 
(increase or decrease) in the response (benchmark response, BMR). In PROAST output for 162 
continious data, terms critical effect size (CES) and critical effect dose (CED) are used instead 163 
BMR and BMD, respectively (Slob and Pieters, 1998) and thus will be employed in the paper. 164 
The CEDL and CEDU values represent the lower and upper 90% (default value in PROAST 165 
software) CED confidence intervals, respectively, thus the CEDU-to-CEDL ratio defines the 166 
CED estimate precision (Slob, 2014b). PROAST software calculates confidence interval 167 
bounds by the profile likelihood method (also called the likelihood ratio method). Confidence 168 
interval plots were employed to visually compare differences in potency, in order to take CED 169 
estimation precision into account (Bemis et al., 2016; Wills et al., 2017, 2016a, 2016b). Dose-170 
response relationships across subgroupings (e.g. oximes) can only be termed significantly 171 
different where confidence intervals do not overlap.  172 
CES is defined as a percent change in mean response relative to the background response. 173 
Endpoint specific CES values were calculated on the basis of values of fitted models 174 
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parameters c and var, applying the statistical method established by (Slob, 2017) and built on 175 
a general theory of effect size given in the same framework. 176 
An additional model, equivalent to exponential, where the different CEDs (related to different 177 
subgroups) are expressed as relative potency factors (RPFs) relative to the CED of one of the 178 
subgroups (e.g. the reference chemical) was also applied. In our analysis, CED of oxime 179 
K027 was expressed as RPF relative to the CED of oxime K203, which was set as a reference 180 
compound. This model allowed calculation of confidence intervals for the RPF. 181 
Shematic ilustration of the BMD approach is presented in Figure 1. 182 
3. Results 183 
No lethal oucome was observed during the 60 min period between dosing and euthanasia in 184 
DDVP-treated group nor any oxime-treated group of animals. However, DDVP-treated 185 
animals exhibited muscule fasciculation, tremor, dyspnea and salivation, that was of lower 186 
intensity in animals treated with oxime therapy. 187 
 188 
3.1. Dose-response model selection   189 
Supp. Figure 1A shows dose-response model 5 from both model families (exponential and 190 
Hill) as the best estimate to AChE activity levels measured at 6 dose levels (including zero 191 
dose) for oximes K203 and K027. However, the AIC of the model 5 (AICexp= -62.44, AICHill= 192 
-61.7) was more than two units larger than that of the full model (AICfull= -69.84) indicating 193 
inappropriate fit. The reason was that the response in the top dose group for oxime K027 194 
deviated substantially from the fitted model (the fitted curve did not hit confidence interval 195 
for observed geometric mean response). Thus, we have reanalyzed data leaving out the top 196 
dose group for oxime K027. Reanalysis yielded a significant improvement in a model fit with 197 
fitted models AIC values (AICexp= -64.64, AICHill= -65.14, Supp. Fig.1B) being more than 198 
two units lower than full model’s AIC (-61.04). According to the fitted exponential model, 199 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
parameter b was found to differ significantly between two dose-response curves related to 200 
oxime K027 and K203 (exponential: b-K203=0,001613 i b-K027=0,003566). This implies 201 
that oximes differ in potency to reactivate AChE. This model was further extended with 202 
allowing parameter c (maximum response) to be oxime-dependent, but that assumption was 203 
abandoned in further analysis because AIC value decrease was not significant and at the same 204 
time the 90%-CIs for parameter c were rather wide for both oximes (exponential: c-K203 205 
2.70-12600, c-K027 2.39-3; Hill: c-K203 2.89-Inf, c-K027 0.00-3.32), which would cause 206 
unreliable estimates.  207 
Finally, the process of model selection resulted in Model 5, both from exponential and Hill 208 
family of models, with parameter b being oxime-dependent, as an accurate description of the 209 
obtained datasets. Table 2 summarizes the selected models parameters with 90%-confidence 210 
intervals. 211 
For practical reason of easier folowing the results, as well as the absence of a significant 212 
difference in obtained exponential and Hill model analysis, the results of the exponential 213 
model are presented below in the text, while both families of the models are presented in 214 
Supp. Figures and Tables. 215 
 216 
Table 2 217 
 218 
3.2. Deriving endpoint-specific value for CESs and related CEDs of oximes 219 
Fitting the four-parameter model to in vivo data obtained in this study directly resulted in an 220 
estimate of maximum response (M) and the within-group standard deviation (s) for a 221 
reactivation of AChE by oximes, as given in Supp. Fig. 1B and Table 2. In PROAST notation, 222 
M is equivalent to parameter c (for c>1, i.e. in increasing curves) and it is expressed as a 223 
maximum fold change in response relative to the background (response at dose zero), while s 224 
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is equvivalent to square root (sqrt) of var, which presents within-group variance for the ln-225 
responses. A general theory for defining the effect sizes for continuous endpoints, based on 226 
empirical relationship between M and s, was followed in deriving AChE reactivation-specific 227 
values for CES (Slob, 2017). Maximum reactivation of AChE by oximes was estimated to be 228 
2.7-fold, which was translated into a percent change by subtracting one and multiplying with 229 
100 = 170%, while the within-group standard deviation was estimated to be sqrt (0.014) = 230 
0.12. Considering the confidence intervals for both available parameters (c and var, Table 2) 231 
M may be between 2.4 and 3, while s may be in the range 0.10-0.14. Observed combination of 232 
M and s in our study most closely matches the combination M = 2.5 and s = 0.131, established 233 
by Slob (2017) as quantified empirical relationship between M and s based on in vivo 234 
toxicological studies for various endpoints, including AChE activity. Thus, the value of M = 235 
2.5 was choosen as a representative maximum fold change of a response for our dataset and 236 
associated effect sizes were calculated as follows: 237 
“Large” effect size = M1/2 = 2.51/2 = 1.581-fold increase or 58%, 238 
“Medium” effect size = M1/4= 2.51/4 = 1.257-fold increase or 26%, 239 
“Small” effect size = M1/8 = 2.51/8 = 1.121-fold increase or 12%. 240 
Calculated critical effect doses (CED) at three levels of effect size were: for oxime K027 241 
CED58 = 52, CED26 = 24 and CED12 = 12 µmol/kg and for oxime K203 CED58 = 100, CED26 = 242 
46 and CED12 = 24 µmol/kg (Supp. Figure 2). Additionaly, Supp. Figure 2 (A3, B3, C3) 243 
shows 90%-confidence intervals of estimated CED for both oximes. The same level of effect 244 
size (weather it was large, medium or small) was obtained with lower dose of oxime K027 245 
compared to oxime K203 implying higher potency of oxime K027. This was quantitatively 246 
examined when additional exponential model, which includes calculation of relative potency 247 
factor (RPF) as a model parameter, was fitted to dose-response data combined (Supp. Figure 248 
3). As Supp. Figure 3 shows, oxime K027 was shown to have 1.929 (CI = 1.51, 2.45)-fold 249 
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higher reactivating potency (lower CED) than oxime K203 (CEDK203 = RPF×CEDK027) 250 
considering DDVP-inhibited AChE. RPF value was found to be independent from the value 251 
of CES (constant RPF value was obtained at CES = 12, 26 or 58%), thus being the measure of 252 
comparison of whole dose-response curves among treatment groups. However, as the results 253 
in Supp. Figure 2 (A3, B3, C3) indicate, scaling the CED confidence intervals was changed 254 
with the change in effect size. At small effect size level CED-confidence intervals related to 255 
oxime K027 and K203 largely overlapped implying that potency difference could not be 256 
distinguished (Supp. Figure 2-C3). At medium effect size level CEDU of oxime K027 257 
overlapped CEDL of oxime K203 implying that potency difference could be very small 258 
(Supp. Figure 2-B3). Finally, at the level of large effect size they did not overlap and this 259 
results in higher potency rank of oxime K027 in contrast to K203 (Supp. Figure 2-A3). 260 
Furthermore, precision in CED estimate, expressed as ratio CEDU/CEDL, increased with 261 
increase in effect size (Table 3) resulting in factor 1.6 and 1.7 for oxime K027 and K203, 262 
respectively, showing that the information in dose-response data examined was fairly good.  263 
 264 
Table 3 265 
 266 
4. Discussion  267 
Fitting the dose-response model to datasets obtained in this study resulted in increasing 268 
erythrocyte AChE activity trend as a function of dose for both experimental oximes, K027 269 
and K203, in DDVP-exposed rats. However, for oxime K027 at the top dose of 50% LD50 270 
significant decline of AChE activity was observed, that considerably influenced the fitted 271 
model. Here, it is very important to bear in mind that the fitted models in dose-response 272 
modeling do not reflect any biological mechanism, as well as different biological mechanisms 273 
may play a role at higher doses as compared to lower doses of compounds (Slob, 2002; Slob 274 
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et al., 2005). In this regard, at higher doses intrinsic affinity of an oxime towards intact AChE, 275 
which is identified as one of the limiting factor for the maximum therapeutic concentration, 276 
may be expected (Voicu et al., 2013; Worek et al., 2016). Further, during complex AChE 277 
reactivation process, phosphylated-oxime can be formed, which depending on its stability, can 278 
directly re-inhibit reactivated AChE (Luo et al., 1999; Milatović and Jokanović, 2009; 279 
Radchenko et al., 2008; Worek et al., 2007). Moreover, it has been shown that 280 
dimethylphosphoryl-oxime, expected to be formed by DDVP used in our study, are more 281 
potent re-inhibitors of AChE compared to diethylphosphoryl-oximes (Kiderlen et al., 2000; 282 
Worek et al., 2000). Furthermore, (Pejchal et al., 2008) have found impaired hepatic excretory 283 
function in rats after i.m. administration of K027 at a dose of 50% LD50, which may 284 
contribute to its hepatotoxicity, effect that is identified as one of the toxicities of oximes 285 
(Balali-Mood et al., 2006; Balali-Mood and Shariat, 1998; Marrs and Vale, 2006). Following 286 
on dose-response modeling, aforementioned methodological and biological arguments have 287 
led us leaving out the top dose group of oxime K027 in further analysis, because we had 288 
assumed that profound decrease in AChE activity was due to toxicity phenomenon caused by 289 
oxime itself. 290 
The purpose of dose-response modeling is deriving the dose (critical effect dose, CED) 291 
associated with predefined, biologicaly meaningfull size in response/effect (critical effect 292 
size, CES). However, the main practical difficulty that arised in our analysis, during modeling 293 
AChE activity as a function of oxime dose, was defining the value of CES, that should 294 
quantify the level of AChE activity, biologically significant from an antidotal treatment 295 
perspective. BMD analysis has been already used for AChE activity as an endpoint, but as a 296 
result of inhibition process by OPs and in terms of human health risk assessment, where 20% 297 
is accepted as an effect size with no major health consequences for AChE activity in serum 298 
(EFSA, 2011). In our experiment AChE activity is perceived as a consequence of reactivation 299 
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process by oximes after inhibition by OP-model compound. Thus, CES presents a fold-change 300 
or %-change in AChE activity relative to its activity at zero oxime dose, or more specifficaly, 301 
relative to the AChE activity in solely DDVP-treated experimental group. This is the main 302 
difference in expression of the effect size from the traditional practice used in oxime in vivo 303 
evaluations, where AChE activity is expressed as % relative to the untreated control (neither 304 
OP nor oxime administered). Traditionally expressed, biologicaly meaningful levels of AChE 305 
activity in different tissues have been reported so far: erythrocyte AChE activity above 30% 306 
of normal level was associated with normal muscule function in pesticide OP-poisoned 307 
patients (Thiermann et al., 2005); in vitro mouse hemidiaphram AChE activity at 30-40% 308 
from the normal level restore muscle function in presence of paraoxon (Thiermann et al., 309 
2010); the minimal level of AChE activity in the pontomedullar area necessary for the 310 
survival of nerve agent-intoxicated mice was assessed to be about 5-20% (Bajgar, 1991; 311 
Bajgar et al., 1975, 1972, 1971). However, according to our best knowledge, available 312 
literature does not allow seting true limits for a minimum extent of AChE reactivation in 313 
different tissues granting the survival of an intoxicated organism.  314 
Recently, (Slob, 2017) has established practicly applicable theory for determination of 315 
meaningful CESs for toxicological endpoints. Basis of the theory is the fact that the way of 316 
expressing the treatment impact is different among different biological endpoints with 317 
maximum response (M, maximum fold change in response relative to background) and 318 
within‐group standard deviation (s, i.e. variability in response measurements obtained 319 
between animals in a dose‐group) being the characteristics of an endpoint (Slob and Setzer, 320 
2014). As a result of dose‐response analysis of in vivo datasets for 27 different endpoints, 321 
including AChE activity, quantitative relationship between M and s was defined, with method 322 
for calculation of CESs at three levels of effect size termed large, medium and small (for 323 
details see results part and Slob 2017). Applying aforementioned statistical approach to the 324 
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maximum response of 2.7-fold and variance of 0.014, obtained for oximes K027 and K203 in 325 
our study, yielded AChE activity-specific CESs of 58, 26 and 12% (large, medium and small, 326 
respectively). 327 
Setting the CES in dose-response modeling generates associated CED, being influenced by 328 
the complete dose-response curve. However, essential output from a dose-response analysis is 329 
CED confidence interval, which represents the range in which the true CED lies. It has been 330 
recently shown that comparisons of CED confidence intervals, as opposed to direct 331 
comparison of single metric (i.e. CED, CEDL or CEDU), comprises a robust way to quantify 332 
differences in genotoxic potencies of compounds (Bemis et al., 2016; Soeteman-Hernández et 333 
al., 2015; Wills et al., 2017, 2016a, 2016b). Considering CED confidence intervals for the 334 
purpose of comparison between oximes K027 and K203 in reactivating eritrocyte AChE in 335 
our study revealed that dose-response relationships and potency estimates (e.g. CEDs) are 336 
significantly different at 58% effect size where their CED confidence intervals did not overlap 337 
resulting in statistically supportable 1.929-fold higher potency/lower therapeutic dose of 338 
oxime K027. Identifying therapeutic doses (CED58) of oximes has allowed calculation of 339 
therapeutic indexes in terms of evaluation efficacy in relation to their toxicity (median lethal 340 
doses, LD50, Antonijevic et al., 2016) as follows: 341 
Therapeutic index, TI = LD50/CED58  342 
TIK027 = 2528 µmol/kg /52 µmol/kg = 49 vs. TIK203 = 716 µmol/kg /100 µmol/kg = 7.   343 
Broader therapeutic index of oxime K027 along with its lower efficacious dose makes it more 344 
beneficial compared to oxime K203 in respect of therapeutic dosage regimes of oximes, that 345 
include two clinical approaches: repeated intermittent administration or continuous infusion 346 
following loading dose (Eddleston and Chowdhury, 2016). 347 
In conclusion, in this study we have utilized the comperhensive combined BMD 348 
methodology for the purpose of analysing and quantitative comparing in vivo dose-response 349 
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data on AChE activity against dose of two experimental oximes, promising reactivators of 350 
OP-inhibited AChE. We have identified that dose-response relationship for AChE activity as 351 
an endpoint in oximes activity to reactivate OP-inhibited enzyme, could be adequately 352 
described by 4-parameter exponential and Hill models, suggesting the new endpoint for BMD 353 
analysis. More specifically, we have determined dose-response relationships for experimental 354 
oximes K027 and K203 considering reactivation of DDVP-inhibited AChE, described by 355 
model m5-b (y=a[c-(c-1)exp(-bxd)]) with parameters a = 0.01453, b-K027 = 0,003566, b-356 
K203 = 0,001613, c = 2.692 and d = 1.208 (i.e. exponential model). Further, oxime K027 was 357 
shown to be 1.929-fold more potent oxime compared to oxime K203 considering that 58% 358 
increase in AChE activity was achived with dose CED58-K027 = 52 µmol/kg (confidence 359 
interval 40, 66 µmol/kg) in contrast to CED58-K203 = 100 µmol/kg (confidence interval 76, 360 
129 µmol/kg). However, at effect sizes up to 26% it could be assumed that reactivating 361 
potencies of oximes K027 and K203 might be the same (overlapping CED confidence 362 
intervals). Thus, we have cofirmed that comparison of CED confidence intervals, in contrast 363 
to a single CED value, presents robust approach to more apparently rank the potenties of 364 
compounds. 365 
Finally, we have made efforts to define CES for oximes K027 and K203 for the purpose of 366 
their efficacies comparison in our experimental dataset. Defining biologicaly meaningful 367 
effect size along with the combined BMD covariate method, would improve the value of 368 
experimental data on AChE activity versus oxime dose and provide robust, comparable 369 
estimates and interpretations of oximes efficacies. 370 
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Fig. 1. Schematic illustration of the benchmark dose (BMD) approach, using hypothetical 591 
continous data. In accordance with PROAST software (v65.5, RIVM, The Netherlands) 592 
notation equivalent term - critical effect dose (CED) is used for continuous data and it has 593 
been applied in this representation. Both response and dose are plotted on the log10-scales. 594 
The triangles represent observed geometric mean responses, along with their 90%-confidence 595 
intervals, at different tested doses. The solid curve is the best fitted dose–response model. 596 
CED is determined from a fitted model as a dose that elicits a pre-specified change in 597 
response, denoted critical effect size (CES or equivalent benchmark response, BMR). CES in 598 
continuous data is defined as a percent change in mean response relative to the background. 599 
The dashed curves represent, respectively, the upper and lower 90% confidence bounds (two-600 
sided) for the effect size as a function of dose. Their intersections with the horizontal line are 601 
at the lower and upper bounds of the CED, denoted CEDL and CEDU, respectively. Thus the 602 
CEDU-to-CEDL ratio represents the CED estimate precision for a single dataset. 603 
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Table 1  
Chemical structures, names, molecular weights, tested doses and routes of administration of OP insecticide dichlorvos and 
oximes in male Wistar rats. 
Chemical structure Chemical name Molecular 
weight  Dose Route  
    (g/mol) (µmol/kg) 
 
 
 
dichlorvos (DDVP) 
220.98 30 s.c. O,O-dimethyl-O-2,2-
dichlorovinylphosphate 
 
 
 
oxime K027 
446.14 0/31/63/126/632/1264 i.m. 4-carbamoyl-1-(3-{4-hydroxyiminomethylpyridinium-1-
yl}propyl)pyridinium dibromide 
 
 
oxime K203 
458.15 0/9/17/35/179/358 i.m. 
4-carbamoyl-1-[(2E)-4-{4-
hydroxyiminomethylpyridinium-1-
yl}but-2-en-1-yl]pyridinium 
dibromide 
s.c-subcutaneously, i.m-intramuscularly 
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Table 2  
Parameters of exponential and Hill model m5-b, with 90%-confidence intervals (CI), that 
describe reactivation of DDVP-inhibited AChE as a function of oxime K027 and K203 dose 
in rat erythrocytes. 
 
AIC-Akaike information criterion; var-variance, a-background response, b-potency, c-maximum response,  
d-steepness. 
 
 
 
 
 
 
 
  Exponential m5-b Hill m5-b 
 y = a [c – (c-1)exp( - bxd)] y = a [1 + (c-1)xd/(bd+xd)] 
parameter value 90%-CI value 90%-CI 
AIC -64.64 - -65.14 - 
var- 0.0143 0.0108-0.0202 0.0144 0.0107-0.0201 
a- 0.7916 0.7500-0.8340 0.7966 0.7550-0.8380 
b-K027 0.003566  0.00107-0.00903 80.85 43.6-69.7 
b-K203 0.001613 0.00038-0.00476 154.5 80.5-137 
c- 2.692 2.43-2.99 2.77 2.47-3.19 
d- 1.208 0.99-1.50 1.503 1.17-1.95 
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Table 3  
Critical effect doses (CED, µmol/kg) of oximes K027 and K203 with 90%-confidence 
intervals (lower, CEDL and upper, CEDU bound) and uncertainty measure (CEDU/CEDL 
ratio) at three levels of critical effect size (CES) concerning reactivation of DDVP-inhibited 
AChE  in rat erythrocytes. 
  
Exponential m5-b Hill m5-b 
K027 K203 K027 K203 
CES=58% CED 51.9 100.0 50.1 95.8 
CEDL 40.2 75.7 39.2 72.4 
CEDU 65.7 129.0 63.2 124.0 
CEDU/CEDL 1.6 1.7 1.6 1.7 
CES=26% CED 24.2 46.6 25.1 48.0 
CEDL 16.8 31.8 18.0 33.2 
CEDU 33.1 65.7 33.5 67.4 
CEDU/CEDL 2.0 2.1 1.9 2.0 
CES=12% CED 12.3 23.7 14.1 27.0 
CEDL 7.5 14.3 9.0 16.6 
CEDU 18.6 37.1 20.7 41.9 
CEDU/CEDL 2.5 2.6 2.3 2.5 
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Oximes K027 and K203 reactivate DDVP-inhibited AChE in rat erythrocytes in dose-dependent 
manner. 
4-parameter exponential and Hill models describe dose-dependence of AChE reactivation by 
oximes K027 and K203. 
Maximum size of reactivation of DDVP-inhibited AChE by oximes K027 and K203 was 2.7-
fold. 
More potent dose-response curve belongs to oxime K027 with relative potency factor of 1.929. 
 
 
